2022 ACC Consensus on Role of Nonstatin Therapies for LDL-Cholesterol Lowering
Since the 2018 guideline’s publication, additional non-statin therapies such as bempedoic acid, evinacumab, and inclisiran, have been approved by the FDA for the management of hypercholesterolemia.
Mickenzie Meyers University Of Minnesota Blood Cholesterol Additional Non Statin Cost Considerations Non Statin Therapies
Source: pharmacytimes.com